Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

key information

study id #: NCT03153319

condition: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI

status: Recruiting


Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.

intervention: Adalimumab Injection [Humira], Saline Solution for Injection


last updated: February 26, 2022